Drugs to reduce liver scarring in chronic hepatitis C

This trial tests whether atorvastatin (a cholesterol medicine) can lower the chance of liver cancer (HCC) in people with advanced liver scarring or cirrhosis. Participants are compared to placebo (inactive pill) while researchers track safety and cancer risk.

This trial tests whether adding a zinc supplement to standard hepatitis B treatment can reduce liver scarring (fibrosis) in patients with moderate scarring. It may help improve liver health and prevent further damage.

This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.

This trial studies whether simvastatin (a cholesterol medicine) can improve or slow scarring of the liver caused by long-term alcohol use. Participants must have confirmed liver fibrosis on biopsy and be in a stable (compensated) phase of liver disease.

This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.

This study aims to develop better ways to measure how much fibrosis (scarring) in the liver improves after treatment for NASH (fatty liver with inflammation). If you have moderate to severe liver scarring from NASH, this research could help doctors track your condition more precisely, which may lead to more effective care.